Neuroone Medical Technologies (NMTC) Net Income towards Common Stockholders (2010 - 2026)

Neuroone Medical Technologies has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 8.14% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$6.6 million (down 0.61% YoY), and the FY2025 full-year result was -$3.6 million, up 70.73% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.1 million, down from -$1.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $1.8 million in Q4 2024, with the low at -$3.5 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged -$2.3 million across 5 years, with a median of -$2.8 million in 2022.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders surged 153.37% — and 2025, when it sank 180.54%.
• Neuroone Medical Technologies' Net Income towards Common Stockholders stood at -$1.7 million in 2022, then slumped by 93.04% to -$3.3 million in 2023, then surged by 153.37% to $1.8 million in 2024, then sank by 180.54% to -$1.4 million in 2025, then sank by 45.05% to -$2.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.1 million (Q1 2026), -$1.4 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.